At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses his study on the influence of cut points for the proliferation marker, Ki67, in clinical decision-making in breast cancer patients, and suggests that Ki67 could be used as a continuous marker in this setting.
